RELIEF THERAPEUTICS HOLDING ORD SHS EBIT

The latest EBIT for RLFTF is $-33M as of June 2026. That compares with $-26M in the prior-year period — down 26.5% year over year. That is below the Healthcare sector average of $110B. Investors often review this figure alongside RELIEF THERAPEUTICS HOLDING ORD SHS's historical trend and sector peers before judging valuation or financial health.

Over the past year, RLFTF's EBIT moved from $-26M to $-33M — a 26.5% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in RELIEF THERAPEUTICS HOLDING ORD SHS's operating scale or balance-sheet position.

Against Healthcare companies, RLFTF currently prints $-33M for EBIT, while the sector average sits near $110B. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at RELIEF THERAPEUTICS HOLDING ORD SHS's growth, margins, and balance sheet.

A EBIT figure of $-33M for RLFTF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $110B. Explore the charts below for those layers of context.

After noting RLFTF's EBIT ($-33M), review year-over-year change from $-26M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.